Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
RESEARCH TOOLSreports
PCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.16 - $31.67
Previous CloseN/A
Volume54.84K
Average Volume (3M)838.46K
Market Cap
$1.19B
Enterprise Value$884.93M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Feb 27, 2025EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding46,173,240
10 Day Avg. Volume658,208
30 Day Avg. Volume838,462
Standard Deviation0.12
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.73
Price to Cash Flow (P/CF)5.60
P/FCF Ratio5.50
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.80
Enterprise Value/Ebitda38.61
Forecast
1Y Price Target
$28.57Price Target Upside10.99% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
Pacira Pharmaceuticals News
PremiumCompany Announcements
Pacira Pharmaceuticals Implements New Board Leadership for Growth
PremiumCompany Announcements
Pacira Pharmaceuticals Announces Leadership Changes and Plan Amendment
---
Bulls Say, Bears Say
Bulls Say
Litigation SettlementThe likelihood of an Exparel settlement with eVenus/Jiangsu Hengrui is considered high, which contributes to a positive outlook for the stock.
Patent ProtectionPCRX continues to add Exparel patents, effectively bolstering patent protection and creating hurdles for competitors.
Revenue PerformanceThe company reported preliminary fourth-quarter revenue above Street expectations.
Bears Say
Exparel Value PropositionMixed KOL commentary from a Weill Cornell anesthesiologist raises questions about Exparel's value proposition.
Generic ThreatWhile the threat of a generic Exparel remains an overhang, it's likely an overstated given the minimal expected impact of a single generic.
Patent InvalidationConcern about Exparel exclusivity following the patent invalidation which hit the stock.
---
Ownership Overview
2.84% Insiders
21.48% Mutual Funds
14.93% Other Institutional Investors
24.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $11.16 and its highest was $31.67 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.19B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.704 by $0.086.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.84.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,173,240 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.79 in its last earnings report, beating expectations of $0.704. Following the earnings report the stock price went up 0.17%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
---
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.57 (10.99% Upside)
$28.57 (10.99% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 21.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.79%
12-Months-Change
Fundamentals
Return on Equity
-12.10%
Trailing 12-Months
Asset Growth
-0.83%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
PCRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a cautiously optimistic outlook with significant advancements in market access, gene therapy development, and financial stability. However, challenges remain, particularly around patent litigation and flat ZILRETTA sales.Read More>---
PCRX Stock 12 Month Forecast
Average Price Target
$28.57
▲(10.99% Upside)
Technical Analysis
Schnitzer Steel Industries
―
Supernus Pharmaceuticals
―
Eagle Pharmaceuticals
―
Corbus Pharmaceuticals
―
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
15/41 ratings generated profit
1 Year Average Return
-1.99%
reiterated a buy rating 3 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 36.59% of your transactions generating a profit, with an average return of -1.99% per trade.
---